Skip to main content
SpringerLink
Log in

Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen S-C, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui C-H, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380):157–163

    Article  CAS  Google Scholar 

  2. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D (2009) Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10:147–156

    Article  CAS  Google Scholar 

  3. Taub JW (2009) Early T-cell precursor acute lymphoblastic leukaemia. Lancet Oncol 10(2):105–106

    Article  Google Scholar 

  4. Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C (2017) The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia 31:705–711

    Article  CAS  Google Scholar 

  5. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O’Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209–2221

    Article  CAS  Google Scholar 

  6. Richard-Carpentier G, Jabbour E, Short NJ et al (2020) Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 20(4):212–218

    Article  Google Scholar 

  7. Farhadfar N, Li Y, May WS et al (2020) Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: a case report and review of literature. Hematol Oncol Stem Cell Ther:S1658–S3876

  8. Puglianini OC, Papadantonakis N (2020) Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts. Ther Adv Hematol 11: doi: 10.1177.

  9. Numan Y, Alfayez M, Maiti A et al. (2018) First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol, 2: doi: 10.1200.

  10. La Starza R, Cambò B, Pierini A et al. (2019) Venetoclax and bortezomib in relapsed/ refractory early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol, 3. doi: 10.1200.

  11. Zappone E, Cencini E, Defina M et al (2020) Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. Clin Case Rep 8(10):2000–2002

    Article  Google Scholar 

  12. Zhang X, Li J, Jin J, Yu W (2020) Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen. Ann Hematol 99(2):395–397

    Article  Google Scholar 

  13. DiNardo CD, Keith P, Vinod P et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7–17

    Article  CAS  Google Scholar 

  14. Steensma DP, Baer MR, Slack JL et al Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27:3842–3848

  15. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF (2010) Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 28:556–561

    Article  CAS  Google Scholar 

  16. Welch JS, Petti AA, Miller CA et al (2016) TP53 and Decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 375(21):2023–2036

    Article  CAS  Google Scholar 

  17. Chang C-K, Zhao Y-S, Xu F, Guo J, Zhang Z, He Q, Wu D, Wu L-Y, Su J-Y, Song L-X, Xiao C, Li X (2017) TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. Br J Haematol 176(4):600–608

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank to all members of the study team, the patient, and her family.

Funding

This work was supported by the National Natural Science Foundation of Jiangsu Province (BE2018652), National Natural Science Foundation of Jiangsu Province (Grant No. BK20201168), and the National Natural Science Foundation of China (No. 81700119).

Author information

Authors and Affiliations

  1. National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

    Jinyu Kong, Nan Chen, Mengyun Li, Jian Zhang, Xiaoxia Wu, Lihong Zong, Depei Wu, Baoquan Song & Huiying Qiu

  2. Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

    Nan Chen, Depei Wu, Baoquan Song & Huiying Qiu

Authors
  1. Jinyu Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mengyun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoxia Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lihong Zong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Depei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Baoquan Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Huiying Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J-Y. K, N. C, and M-Y. L collected and analyzed the clinical data and made the summary. J. Z and B-Q. S designed this study and wrote this manuscript. H-Y. Q and D-P. W revised this manuscript. All authors approved the manuscript.

Corresponding authors

Correspondence to Baoquan Song or Huiying Qiu.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Jinyu Kong and Nan Chen are co-first authors

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kong, J., Chen, N., Li, M. et al. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia. Ann Hematol 101, 697–699 (2022). https://doi.org/10.1007/s00277-021-04530-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04530-y

Search

Navigation